Phaseline

Companies › Century Therapeutics

Century Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Immunology; next expected readout Aug 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CNTY-101
Engineered regulatory T cell therapy targeting B cell-mediated autoimmunity
–Phase 1Systemic Lupus ErythematosusAug 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06255028CNTY-101Phase 1Systemic Lupus ErythematosusImmunologyAug 2028

From the company's SEC filings

Cash and short-term investments of $120m on 2026-06-30; operating cash outflow about $91m a year; runway about 16 months at that burn, to Oct 2027

Press releases filed as 8-K in the last year:

Specialist investors

Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.